in this issue
Regions :: China
FDA issues warning letters to API plants in China and India
12:29 PM MDT | June 18, 2014 | Deepti Ramesh
FDA issued separate warning letters earlier this month to the active pharmaceutical ingredient (API) manufacturing facilities of Tianjin Zhongan Pharmaceutical (Tianjin, China) and Apotex (Toronto) located at Tianjin; and Bangalore, India, respectively, for violating cGMP. The warning letters were published on the FDA Web site on 17 June. An FDA inspection from 27–31 January at the Apotex Bangalore facility identified that the manufacture of APIs significantly deviated from cGMP, FDA says. FDA issued an import alert against the Bangalore facility...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee